Document is current
Any future updates will be listed below
-
Authors
Taranu, Daniela https://orcid.org/0000-0001-9165-4437
Balz, Luisa T.
Holbrook, Jill https://orcid.org/0009-0000-6403-6393
Tumani, Visal https://orcid.org/0000-0002-8569-6638
Schreiber, Herbert https://orcid.org/0000-0002-4755-492X
Tumani, Hayrettin https://orcid.org/0000-0002-1647-6201
Uttner, Ingo
-
Funding
Funding for this research was provided by:
Universität Ulm
- License Information
-
More Information
Article History
Received: 17 February 2025
Revised: 22 April 2025
Accepted: 23 April 2025
First Online: 14 May 2025
Declarations
:
: H.S. received grants from Bayer, Biogen, Novartis, Roche and Sanofi and consultancy and speaker`s honoraria from Almirall, Bayer, Biogen, Bristol-Myers-Squibb, Janssen, Novartis, Roche, Sanofi and Teva. H.T. received honoraria as a consultant/speaker and/or for events sponsored by Alexion, Bayer, Biogen, Bristol-Myers Squibb, Celgene, Diamed, Fresenius, Fujirebio, GlaxoSmithKline, Horizon, Janssen-Cilag, Merck, Novartis, Roche, Sanofi-Genzyme, Siemens, Teva and Viatris. No conflicts are relevant to the study. D.T., L.T.B., J.H., V.T. and I.U. declared no conflicts of interest.
: This study was approved by the Ethics Committee of Ulm University (Ethics Code: 157/16) on Sept. 13, 2016. All participants provided written informed consent prior to enrolment in the study. This research was conducted ethically in accordance with the Declaration of Helsinki.
